Increased concentration of circulating clotting factors, faster platelet turnover, and reduced fibrinolytic activity all contribute to the hypercoagulable state in pregnancy.' 2 The thrombotic tendency is offset by an increased cardiac output and more rapid circulation time but the risk of leg vein thrombosis,3 left atrial thromboembolism in mitral stenosis, and thrombosis on prosthetic cardiac valves is increased. 4 Anticoagulant drugs are essential for the prevention of potentially fatal maternal thromboembolic events and the indication for these drugs must therefore be the same in pregnancy as outside it, despite possible risks to the fetus. Controversy continues concerning the magnitude of these risks and the choice and usage of anticoagulants in pregnancy.
count as well as thromboembolic complications in 50% of patients and heparin should be stopped. The overall incidence of thrombocytopenia seems to be reduced with the low molecular weight heparins that cause less platelet aggregation. Heparin can also induce osteoporosis when it used long term. The mechanism of this is unknown. It has been reported most often in pregnant women perhaps because they are more likely to have had long-term treatment. Other side effects include hypersensitivity such as urticaria, bronchospasm, and anaphylaxis.
The dose is judged by the activated partial thromboplastin time (APTT), the kaolin cephalin clotting time, or the plasma heparin concentration. The frequency of testing depends on the route of administration and type of heparin, and regular blood counts are required to detect thrombocytopenia.
Heparin5
Heparin is a natural water soluble mucopolysaccharide first introduced for clinical use nearly 80 years ago to prevent postoperative thrombosis. Commercial heparins are obtained from porcine gut or bovine lung tissue and have molecular weights of up to 40 000 daltons. Low molecular weight heparins of only 3200-6500 daltons were introduced in the hope of reducing adverse side effects. Heparin does not cross the placenta but needs to be given parenterally and its antithrombotic effect is difficult to maintain without bleeding complications. 10 mechanical valve thromboses were reported among 108 mechanical valves.'9 Six of the patients were on heparin, two were unsatisfactorily controlled on an oral anticoagulant, and two were not on any anticoagulant at the time. The thromboembolic risk was 4-5 times higher for women on heparin than for women taking an oral anticoagulant. Wang et al reported five thromboembolic events in ten patients treated with subcutaneous heparin (5000 intravenously twice a day) during the first trimester. Iturbe-Alessio et al, Larrea et al, and Vitali et al also reported valve thromboses, all occurring while their patients were on heparin (in three, three, and two cases, respectively, with five deaths).20 23 25 Transfer from oral anticoagulants to heparin in pregnancy has been widely advocated4044 but no published series justifies this practice. Low dose heparin carries a grave risk of valve thrombosis whereas high doses over a long period when the patient cannot be retained in hospital for observation carry a risk of serious maternal haemorrhage and a considerable risk of fetal death or prematurity caused by retroplacental haemorrhage. It is virtually impossible to achieve continuous anticoagulant control within the very narrow therapeutic index of heparin, which is less safe and less effective than warfarin in preventing valve complications during pregnancy.
Revised US recommendations published in 199245 still advise discontinuing oral anticoagulants during the first trimester and paricularly during the sixth to twelfth weeks of gestation when the fetal skeleton is believed to be most vulnerable to the teratogenic effects of oral anticoagulants. Prolongation of the APTT to one and a half times control (sub-therapeutic) was advised (but since then the recommendation has increased to at least twice the control46) using an adjusted dose of subcutaneous heparin until the thirteenth week of gestation, re-starting warfarin until the middle of the third trimester with subcutaneous heparin recommended until delivery. It seems clear, however, that any period without warfarin puts a pregnant woman with a mechanical prosthesis at risk from valve thrombosis, a complication that can result in the death of both mother and fetus.
No embryopathies were recognised in studies of 36,38 22'9, 53,18 and and 4727 women who took warfarin throughout pregnancy or during the first trimester and the risk of coumarin induced malformation has been estimated to be under 5% based on incidences of between 4% and 79%.20 23 48 Lee et al found a 50% incidence of abortion with subcutaneous heparin even when treatment was adjusted to an APTT of 1-5 as recommended in the United States.24 The changes in coagulation factors during pregnancy demand high doses of heparin49 and the higher doses now recommended in the United States increase the danger of bleeding.
In pregnant women who are treated scrupulously the risks of thromboembolic events are probably no greater than reported in the non-pregnant population with mechanical heart valves and the view has been expressed that in asymptomatic or mildly symptomatic patients with prosthetic heart valves who are willing and able to follow a strict regimen of medical care, pregnancy is not associated with increased morbidity in the mother or fetus. 47 The inevitable re-replacement carries an unpredictable risk of death or disaster while the children, for whom the choice of prosthesis was made, are still young and dependent. These mothers should understand why the use of bioprostheses is otherwise confined to the elderly or others whose life span is likely to be shorter than that of their valve. They should know that premature failure of bioprostheses is expected in young people and is even more rapid in pregnancy and, importantly, that because re-operation is technically more difficult than the first operation it carries more risk and should not be undertaken lightly.
Properly controlled trials of antithrombotic therapy for women with mechanical heart valve prostheses during pregnancy have not been possible because of small numbers and the many variables of valve type, site, and size. Agreement has only been reached about explaining the options to women before valve replacement and before pregnancy.53
Whenever possible women with valve disease should complete their pregnancies before valves are replaced.
